pembrolizumab + ipilimumab

Pembrolizumab + ipilimumab is a combination of two immune checkpoint inhibitors used in cancer immunotherapy. Pembrolizumab is a humanized monoclonal antibody targeting programmed cell death protein 1 (PD-1), while ipilimumab is a monoclonal antibody targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). This combination works by blocking two distinct inhibitory pathways that regulate T-cell activation and immune response, thereby enhancing the body’s ability to mount an antitumor immune response. The dual blockade has shown significant antitumor activity, particularly in advanced melanoma and other cancers, including after progression on prior anti-PD-1/L1 therapy. The regimen typically involves intravenous administration of both agents at specified doses for several cycles, followed by maintenance with pembrolizumab monotherapy[1][2][3][7][8].

Other names

pembrolizumab and ipilimumabpembrolizumab plus ipilimumabpembrolizumab/ipilimumab